

Single Nucleotide Polymorphism of IL-2 Gene at Position +166 in Type 1 Diabetes of Iraqi Patients

Ibtesam, B. Hassan*

Maha F. Nazzal¹

Ibtesam K. Alwan

Department of Biology, College of
Education for Pure Science,
University of Diyala. Iraq

Email: ibtesambh67@gmail.com

Marah S. Hameed

Department of Physiology
Biochemistry and Pharmacology ,
College of Veterinary Medicin and
Surgery, University of Diyala, Iraq

Ali, A. Aabud

Technical Institute of Diyala,
Middle Technical University, Iraq

Abstract : The present study aimed at investigating of frequency of polymorphism of interleukin-2 gene (IL2) at position₊₁₆₆ SNP in Type 1 Diabetes and in healthy controls subjects 39 of Iraqi patients, (12 males and 27 females; 15.65 ± 1.79 years) and 21 controls. (7 male & 14 female ; 14.66 ± 3.43 years) attended the hospital in Baghdad for diagnosis and treatment during the period February 2015 – January 2016 were enrolled in this study, the polymorphism of IL2₊₁₆₆ was data waved by polymerase chain reaction-specific sequence primer (PCR-SSP) assay. The results showed a comparison IL2₊₁₆₆ genotypes and alleles between T1D patients and controls frequencies of TT genotype and T allele (71.69 vs. 68.95%; P =0.589 respectively) There was a significant increase in patients contrast to controls, (51.38 vs. 48.08%; P =0.312) and associated RR rates were 19.2% & 27.0%, respectively. the related EF values were 1.56 and 1.60 .Similar observations were made in GG genotype. In contrast TG genotype and G allele (23.93 vs. 28.55%, P =1.000 respectively) Low frequency was observed in patients compared to healthy subjects (43.28 vs. 43.22%; P =0.312), and the related PF values were 0.56 and 0.62 , respectively. The results of the study indicate that IL2₊₁₆₆ SNP may have a role in the mechanism of etiopathogenic of T1D in the samples of Iraqi patients

*Key words: Polymorphism, IL-2, T1D,

I. Introduction

Type 1 Diabetes is considered the most common severe chronic autoimmune diseases worldwide. In Europe, it incidence attributed to its occurrence in children, with a predicted 70% rise in disease over the next 15 years. More than 20 million people in Europe suffer from Type 1 diabetes T1D (Todd *et al.*, 2016). T1D is the second most common chronic disease of children, and adults with T1D

parents with this condition (Bonifacio, 2015). It usually appears in childhood, adolescence, or early adulthood, but sometimes it appears later in adult life (Ozougwu *et al.*, 2013; Soren and Grey, 2015). Healthy people have a normal level of insulin hormone But with T1D patients, the pancreatic gland not synthesis insulin or make very little of it (Chisholm *et al.*, 2010; Hartemann and Bourron, 2012). As T1D is an autoimmune disease the immune system attacks and destroys insulin-producing islet β cells. Cytokines play role as pleiotropic polypeptides To regulate inflammatory immune response through its effect on cells. They occur important signals in the pathophysiology of a range of diseases, as in T1D (Elmarakby and Sullivan, 2012; Kyi *et al.*, 2015). There is ample evidence to suggest that polymorphisms in cytokines may play an important role in modifying the immune response. Many cytokines have been found to have an effect in causing pathogenesis of T1D (Chisholm *et al.*, 2010), as at TGF-B1, IFN- γ and IL-1 (Van de Veerdonk and Netea, 2013; Gonzalez and Fernandez, 2008). Mediators of inflammation such as TNF- α , IL-6, IL-2 the IL-10 family of cytokines, IL-18, IL-4 and found that certain chemokine's work on the occurrence of both types of diabetes (Vincenz *et al.*, 2011; Arend and Gabay, 2008; Oo *et al.*, 2012). The contribution of inflammation to diabetes comes from studies by researchers studying the role of inflammatory cytokines in diabetes. One of these cytokines is interleukin-2 (IL-2), which was discovered in 1975 as a growth-promoting activity for bone marrow-derived T lymphocytes (Fallahzadeh *et al.*, 2011). IL2 is encoded by a gene located on the long arm of chromosome 4 (4q26). Two (SNPs) in IL2 gene (-330 T/G & +166 G/T) have been shown to influence IL-2 levels (Gao *et al.*, 2009). It is produced and released from active T cells and plays a major role in the cellular immune response. IL-2 has been found to increase lymphocyte secretion of T, B and NK cells and has many immune effects (Wrenshall *et al.*, 2014). Moreover, it is a strong T cell growth factor that asserts that lymphocytes are amplified in vivo (Fallahzadeh *et al.*, 2011). In humans, allelic variation of the IL-2 receptor gene, IL2RA, encoding

the α subunit (CD25) was identified as a susceptibility determinant for T1D (Francisco *et al.*, 2004). Functionally, it initiates a pro-apoptotic pathway by improving the expression of FasL on activated T cells, and since T cells also activated Fas/CD95, this event leads to apoptosis of activated T lymphocytes. Also, it elevates production of NK-derived cytokines such as tumor necrosis factor alpha (TNF- α), interferon- γ (IFN- γ) and granulocyte monocyte-colony stimulating factor (GM-CSF), and can be synergistically represented with IL-12 to enhance NK cytotoxic activity. (Oo *et al.*, 2012), (Hulme *et al.*, 2012). For all previous information present study focused on Interleukins 2.

II. Materials & Methods

Subjects

The diagnosis and detected of disease was determined by clinical specimens thirty nine patients; (12 males & 27 females) attended the hospital in Baghdad for diagnosis and treatment during the period February 2015 – January 2016 in addition to twenty one healthy controls (7males and 14females).According to diagnosis after an overnight fasting on food about 10–12 h for all investigations. Blood samples were collected in EDTA. The specimens were stored in deep freeze at -20°C. T1D patients and randomly Collected healthy controls (HC). The patients age range was 15.65 \pm 1.79 years compared subject of health's controls was 14.26 \pm 1.43 years, were record in the study.

Detection of IL2 Polymorphism

Genomic DNA was extracted from EDTA blood using Wizard Genomic DNA Purification Kit (Promega, USA). followed by electrophoresis on 2% agarose-gel by CTS-PCRSSP Tray Kit (Heidelberg, Germany) .

Statistical Analysis

Genotypes of $IL2_{+166}$ SNP were presented as percentage frequencies, These estimations were calculated by using the WINPEPI computer programs for epidemiologists. The latest version of the WINPEPI package is available free online at <http://www.brixtonhealth.com>.

III. Rustles

SNP of $IL2$ gene was determined in the promoter region at position $+166$ ($IL2_{+166}$ SNP), it was presented with three genotypes (TT, TG and GG) that correlate with two alleles (T and G).Among T1D patients, no significant difference was observed between the observed and expected frequencies of the three genotypes (a good agreement with Hardy-Weinberg equilibrium; HWE), while in controls, a departure from HWE was observed (i.e. a significant difference between the observed and expected genotype frequencies they were significantly deviated in controls ($P \leq 0.001$).) however comparing patients to controls results some significant differences (Table -1).The frequencies of

TT genotype and T allele were significantly increased in patients (71.69 & 68.95%, respectively) compared to controls (51.38 & 48.08%, respectively). The relative risks (RRs) of such positive associations were 19.2% and, 27.0% respectively .Similar observations were made in GG genotype(40.51vs. 33.33%, $R = 11.8\%$ respectively). In contrast, TG genotype & G allele frequencies were significantly decreased in patients (23.93 & 28.55%, respectively) compared to controls (43.28 & 38.98%, respectively).The preventing fractions (PFs) of such negative associations were 0.56 & 0.62, respectively. (Table -2).

I. TABLE 2--STATISTICAL ANALYSIS OF ASSOCIATIONS BETWEEN $IL2_{+166}$ GENOTYPES OR ALLELES IN DIABETES TYPE 1 PATIENTS AND CONTROLS

Type of Comparison	Statistical Evaluation			Fisher's Exact Probability	95% Confidence Intervals
	$IL2_{+166}$ Genotype or Allele	Relative Risk	Preventive or Fraction Etiological		
Diabetes Disease Versus Controls.	TT	19.2%	1.56	0.589	0.55 - 4.43
	TG	16.7%	0.56	0.381	0.18 - 1.71
	GG	11.8%	1.10	1.000	0.30 - 4.07
	T	27.0%	1.60	0.312	0.74 - 3.48
	G	14.5%	0.62	0.312	0.29 - 1.35

IV. DISCUSSION

According to the presented results, $IL2_{+166}$ SNP” can be highlighted as an important genetic marker in the pathogenesis of T1D was presented with three genotypes (TT, TG and GG) that corresponded to two alleles (T and G). These genotypes were in a good agreement with Hardy-Weinberg equilibrium (HWE) in patients, but they were significantly deviated in controls ($P \leq 0.001$). present study illustrated that $IL2_{+166}$ important genetic marker in the “pathogenesis of T1D especially if we consider RR values was 19.2% & 27.0% it was showed that frequency of TT genotype and T allele (71.69 vs. 68.95%; $P = 0.589$ respectively) were significantly rise in patients contrast to controls, (51.38vs. 48.08%; $P = 0.312$), and the associated EF values were 1.56 & 1.60, respectively. Similar observations were made in GG genotype(40.51vs. 33.33%; $R = 11.8\%$). In contrast, TG genotype and G allele (23.93vs. 28.55%, $P = 0.381$ respectively) frequencies were significantly decreased in patients, compared to controls (43.28vs. 38.98%; $P = 0.312$), and the associated PF values” were 0.56 and 0.62 respectively. The presented results strongly suggest that $IL2_{+166}$ polymorphism is involved in T1D in terms of susceptibility (positive association) and protection (negative association); especially in whom the RR of GG genotype. (Table 1 and 2). Therefore, $IL2$ allelic changes at position $+166$ might be associated with increased and decreased risk of T1D in Iraqi population, and this may also contribute to a better clinic diagnosis. Such conclusion has also been favored by Dogan, and co-workers (2006) who investigated the prevalence of $IL2_{+166}$ polymorphism in 27 Turkish T1D patients and 25 controls, and reported similar findings.. According to these finding which agrees with previous results, can concluded that $IL2_{+166}$ SNP might have a role in the etiopathogenic mechanism of T1D, multiple studies have been conducted testing the ability of

IL-2 supplementation to prevent and reverse type 1 diabetes in the NOD mouse. Overall, these studies support the notion that exogenous IL-2 treatment can protect NOD mice from diabetes development, (Francisco *et al.*, 2004; Oo *et al.*, 2012; Chentoufi *et al.*, 2011). Results of a study conducted in Egypt showed significant differences in genotype GT in patients with T1D (*EL-MOHAMADY et al.*, 2009). However, other studies investigated Type 1 diabetes subjects are reported to exhibit reduced IL-2 production and subsequent Treg dysfunction (Hulme *et al.*, 2012) These cells depend on IL-2 for proliferating and controlling the T effector cells (Teff) reaction, but they do not have the capacity to produce IL-2. In type 1 diabetes (T1D), a hypothesis is that a lack of IL-2 in pancreas could prevent Tregs action and lead to beta cells destruction (Hartemann and Bourron, 2012; Connor *et al.*, 2016) . These interleukins IL-2, IL-1, IFN- γ and TNF stimulate T-cytotoxic cells and are effective in destroying insulin-producing beta cells in patients with T1D(22). SNPs of IL2 might have a role in etiopathogenesis of T1D.

v. Conclusion

- 1- That frequency of TT genotype and *T allele* were significantly rise in patients contrast to controls associated with a risk of developing T1D while *G allele* and TG genotype showed association with to prevention of the risk of the disease.
- 2- IL2 allelic changes at position +166 might be associated with increased and decreased risk of T1D in Iraqi population, and this may also contribute to a better clinic diagnosis.
- 3- SNPs of *IL2* might have a role in etiopathogenesis of T1D.
- 4- There are no local studies on IL-2 in T1D of Iraqi patients. this is the first study.

VI. References

Arend,W.P.; Palmer, C. and Gabay, C. (2008).IL-1,IL-18, and IL-23 families of cytokines. Immunol. Rev., 223:20-38.

Bonifacio, E. (2015). Predicting Type 1 Diabetes Using Biomarkers. J. Diabe.Care . Jun. ; 38(6): 989-996

Chentoufi, A.A.; Gaudreau, S.; Nguyen, A.; Sabha, M.; Amrani, A. and ElGhazali, G (2011). Type I Diabetes-Associated Tolerogenic Properties of Interleukin-2. Clinical and Developme. Immunolo., Vol., Article ID 289343, 9 pages.

Chisholm, A.O.; Best, J.; Frazer, I.; Pawlak, D.; Townend, J. and Twigg, S. (2010).Australian Type 1 Diabetes Research Agenda - Partnering science,

government and the community. The Juvenile Diabetes Research Foundation. Sydney, 2nd edition.pp.1-79.

Connor, J.; Dwyer, N.C.; Ward, A. P. and Thomas, R. M. (2016). Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2. Curr. Diab. Repo. June 2016, 16:46.

[Dogan, Y.](#); [Akarsu, S .](#); [Ustundag, B.](#); [Yilmaz, E .](#) and [Gurgoze, M.K.](#) (2006). Serum IL-1 β , IL-2, and IL-6 in Insulin-Dependent Diabetic Children. [Mediat. Inflamm.](#) (1): 59206

Elmarakby, A.A. and Sullivan, J.C. (2012). Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy. Blackwell Publishing Ltd. Cardio. Thera.s 30 :49–59.

EL-mohamady, I.; Haron, M.; Rashed, L.; Halawa, E.; badawy N. and Sediek H. (2009). **Cytokines in Egyptian Children with Type 1 Diabetes**, Cat.: Vol. 77, June, Hits: 329 .

Fallahzadeh, M. K.; Roozbeh, J.; Geramizadeh, B. and Namazi, M. R.(2011). Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol. Dial. Transp., 26(10): 3338-44.

Francisco, P. B.; Oyarzún, A.A.; Carrasco,E.P.; Angel, B.B.; Albala,C.B.; Luis, J. and Santos, M. (2004).Plasma levels of interleukin-1 β , interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with β -pancreatic auto antibodies.Rev.Méd.Chile.; 132: 413-420.

Gao, Q.; Liu, D.; Zhang, S.; Jia, M.; Wang, L.; Wu, L.; and Tong, L. (2009). Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. W. J. G., 15:5610-5619.

Gonzalez, J.F.N. and Fernandez, C.M. (2008). The Role of Inflammatory Cytokines in Diabet Padgett, L. E., Broniowska, K. A., Hansen, P. A., Corbett, J.

A. and Tse, H. M. (2013). The role reactive oxygen species and proinflammatory cytokines in type1 diabetes pathogenesis. Ann. N.Y. Acad. Sci. 1281:16-35.ic Nephropathy.J. Am. Soc. Nephrol. 19: 433–442.

Hartemann, A. and Bourron, O. (2012). Interleukin-2 and type 1 diabetes: new therapeutic perspectives. Diabe. Metab. Nov; 38(5): 387-91.

Hulme, M.; Wasserfall,C.; Atkinson, M. and Brusko, T. M. (2012). Central Role for Interleukin-2 in Type 1 Diabetes. Diabe. 61(1):14-22.

Kyi, M.; Wentworth, J. M.; Nankervis, A. J.; Fourlanos, S. and Colman, P. G. (2015). Recent advances in type 1 diabetes. Med. J. Aust; 203 (7): 290-293.

Oo, Y .; Mutimer, D. and Adams, D. (2012). Low-dose interleukin-2 and HCV-induced vasculitis. *N Engl J. Med.*, 366:1353-1354.

Ozougwu, J. C.; Obimba, K. C.; Belonwu, C. D.; and Unakalamba, C. B.(2013). The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. *J. Physiol.and Pathophysiol.*, Vol. 4(4), pp. 46-57.

Padgett, L.E.; Broniowska, K.A.; Hansen, P.A.; Corbett, J.A. and Tse, H.M. (2013). The role reactive oxygen species and proinflammatory cytokines in type1 diabetes pathogenesis. *Ann. N.Y. Acad. Sci.* 1281:16-35.

Soren, K. and Grey, M. (2015). Depression, Anxiety, and Eating Disorders Are Common in Teens and Young Adults with Type 1 Diabetes .Vertical Health, LLC.<http://www.endocrineweb.com>.

Todd, J.A.; Evangelou, M.; Cutler, A.J. Pekalski, M.L.; Walker, N.M.and Stevens, H.E. (2016) Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised,

Open Label, Adaptive Dose-Finding Trial. *PLoS Med* 13(10): e1002139.

Van de Veerdonk, F.L. and Netea, M.G.(2013).New insights in the Immunobiology of IL-1 family members. *Front. Immunol.* 8(4):167.

Vincenz, L.; Szegezdi, E. ; Jäger, R.; Holohan, C.; Brien, T.O. and Samali, A. (2011). Cytokine-Induced β -Cell Stress and Death in Type 1 Diabetes Mellitus, Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments, Prof. Chih-Pin Liu (Ed.), ISBN: 978-953-307-756-7,

Wrenshall, L. E.; Clabaugh, S. E.; Cool, D.R.; Arumgan, P.; Grunwald, W.C.; Smith, D. R.; Liu, G.C. and Miller, J. D. (2014).Identification of a cytotoxic from of dimeric interleukin -2 in murine tissues. *Pols. One.* Jul., 14;9(7): e 102191.